Core Points - AB Science has announced the issuance of a Canadian patent for AB8939, which protects its composition and use in treating acute myeloid leukemia (AML) until 2036 [1] - The patent completes the intellectual property coverage for AB8939 across all key geographic areas, including Europe, USA, China, Japan, South Korea, India, Israel, Latin America, and Australia [2] - AB8939 is a novel microtubule destabilizer currently in early phase clinical trials for AML, with the first phase focusing on determining the maximum tolerated dose [3] - The drug is also eligible for regulatory data protection in Canada, preventing generic competition for 8 years post-approval, and has received orphan drug designation from EMA and FDA, providing additional market exclusivity [4] - A separate patent application has been filed to protect AB8939 for treating AML with specific chromosomal abnormalities, potentially extending protection until 2044 [5] - AB8939 targets cancer cells by destabilizing microtubules and inhibiting enzymes essential for cancer stem cell survival [6] - AB Science specializes in developing protein kinase inhibitors for diseases with high unmet medical needs and has a portfolio of molecules including masitinib [7][8]

Core Points - The European Medicine Agency (EMA) has approved the extension of the shelf-life of AB Science's veterinary medicine MASIVET® from 36 months to 48 months [1] - MASIVET® is approved for treating non-resectable dog mast cell tumors (Grade 2 or 3) with confirmed mutated c-kit tyrosine kinase receptor and is available in all EU countries [2] - The shelf-life extension provides flexibility for patients, caregivers, and AB Science in managing inventory levels, reducing the risk of product expiration, and ensuring continuity of therapies [3] Company Overview - AB Science, founded in 2001, specializes in the research, development, and commercialization of protein kinase inhibitors (PKIs) targeting diseases with high unmet medical needs [4] - The company's lead compound, masitinib, is registered for veterinary medicine and is also being developed for human medicine in various fields including oncology and neurological diseases [5]

Company Announcement - AB Science SA has postponed the publication of its 2024 annual financial report from April 30, 2025, to May 9, 2025, to allow auditors to complete their work [1][2] Company Overview - AB Science, founded in 2001, is a pharmaceutical company focused on the research, development, and commercialization of protein kinase inhibitors (PKIs) targeting diseases with high unmet medical needs [3] - The company's lead compound, masitinib, is registered for veterinary medicine and is being developed for human medicine in areas such as oncology, neurological diseases, inflammatory diseases, and viral diseases [4] Additional Information - AB Science is headquartered in Paris, France, and is listed on Euronext Paris under the ticker AB [4] - Further information can be found on the company's website [5]